English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Dose optimized PIP/TAZ utilizing prolonged infusion has been shown to improve clinical outcomes. Previous pharmacokinetic studies of these prolonged infusion PIP/TAZ doses that achieve adequate time above minimum inhibitory concentration (T>MIC) in non-obese patients do not achieve similar concentrations in obese patients. Due to this higher doses are necessary in obese patients to achieve adequate T>MIC. Our institution utilizes weight-based dose optimization of PIP/TAZ in obese patients. The purpose of this study was to investigate clinical outcomes and adverse events with these dosing strategies compared with optimized doses in non-obese patients Methods A retrospective single-center cohort study was conducted in patients ≥18 years old with culture-confirmed non-urinary tract Pseudomonas aeruginosa infections. Patients with positive cultures and PIP/TAZ treatment ≥24 hours were classified in groups as obese (≥120 kg) or non-obese (<120 kg). Results 44 patients were studied in each arm with mean age 56 ± 13.8 and 65 ± 17.5, median weight 144 [132–170] and 77 [65–99] and median BMI 48 [40.5–56.2] and 26.4 [21.8–29.7] in the obese and non-obese groups respectively. Outcomes in obese compared with non-obese included composite clinical cure/improvement 86.4% and 77.2%, length of stay 8 and 10 days, ICU length of stay 10 and 8 days, hospital mortality 9.1% and 11.3%, 30 day mortality 15.9% and 18.2%, respectively. Adverse events in obese and non-obese groups occurred at 34.1% and 27.3% including AKI at 27% and 16% and thrombocytopenia at 7.1% and 12.8%, respectively. PIP/TAZ was discontinued due to safety concerns in 1 obese patient and 2 non-obese patients. Conclusion Weight-adjusted PIP/TAZ doses in obese patients produce similar clinical outcomes to optimized doses in non-obese patients. Disclosures All authors: No reported disclosures.

open forum infectious diseases

2440. Weight-Adjusted Piperacillin–Tazobactam (PIP/TAZ) Therapy in Obese Patients vs. Optimized Doses in Non-obese Patients: A Retrospective Cohort Study